UVERITE—A MILL ADDITION OPACIFIER FOR PORCELAIN ENAMEL*

Uverite is the trade name for an antimony-titanium opacifier, having an approximate formula of 7CaO·CaF₂·6TiO₂·2Sb₂O₅. When compared with tin oxide in a range of commercial enamels, it has proved to be equivalent in its effect on opacity, color, gloss, firing range, general workability, and durability.     

AN IMPROVED VOLUMENOMETER*

A volumcnometer of improved design has been developed for measuring the solid volumes of specimens varying in size up to that of standard refractory bricks. The chief feature of the new design is the use of a closed-cistern, altitude-type mercurial barometer to replace the simple manometer previously used. The barometer is de signed for use in a constant temperature room (21.1°C.) where the acceleration of gravity is 980.1 cm. per sec.². Under these conditions, pressure readings are auto matically corrected to standard conditions. A vernier permits rapid readings to 0.1 mm. of mercury.     

SELENIUM BLACK GLASS*

A black glass was made by melting a soda-lime-silica glass under a reducing atmosphere with the addition of 0.6% of selenium and 0.1% of cobalt carbonate, CoCO_s. The light absorption of a specimen about 0.01 inch thick in the range of 400 to 750 mp was superior to that of commercial black glass. The maximum transmission was 27% at 750 mp. The use of nickel and iron oxides is less effective than cobalt oxide for obtaining selenium black glass.     

Golf,golf, and more golf

Journal of the American Oil Chemists' Society -     

Celiac Disease and Neurological Manifestations: From Gluten to Neuroinflammation

Celiac disease (CD) is a complex multi-organ disease with a high prevalence of extra-intestinal involvement, including neurological and psychiatric manifestations, such as cerebellar ataxia, peripheral neuropathy, epilepsy, headache, cognitive impairment, and depression. However, the mechanisms behind the neurological involvement in CD remain controversial. Recent evidence shows these can be related to gluten-mediated pathogenesis, including antibody cross-reaction, deposition of immune-complex, direct neurotoxicity, and in severe cases, vitamins or nutrients deficiency. Here, we have summarized new evidence related to gut microbiota and the so-called “gut-liver-brain axis” involved in CD-related neurological manifestations. Additionally, there has yet to be an agreement on whether serological or neurophysiological findings can effectively early diagnose and properly monitor CD-associated neurological involvement; notably, most of them can revert to normal with a rigorous gluten-free diet. Moving from a molecular level to a symptom-based approach, clinical, serological, and neurophysiology data might help to disentangle the many-faceted interactions between the gut and brain in CD. Eventually, the identification of multimodal biomarkers might help diagnose, monitor, and improve the quality of life of patients with “neuroCD”.